close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

71.47 -2.20 (-2.98%)
Streaming Delayed Price Updated: 12:47 PM EDT, Aug 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal ↗
PTC Therapeutics (NASDAQ:PTCT) plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to... 
Via MarketBeat
Topics Bankruptcy
News headline image
PTC Therapeutics Q2 Earnings Call Highlights ↗
PTC Therapeutics (NASDAQ:PTCT) reported second-quarter total revenue of $361 million and raised its 2026 outlook, citing continued growth from its Sephience launch and greater durability than expected... 
Via MarketBeat
Topics Earnings
PTC Therapeutics (NASDAQ:PTCT) Soars on Q2 Earnings Beat and Raised Guidance ↗
Via Chartmill
Topics Earnings
News headline image
What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million ↗
This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities. 
Via The Motley Fool
Topics Regulatory Compliance
PTC THERAPEUTICS INC (NASDAQ:PTCT) Scores Perfect 10/10 For Technical Breakout Setup ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Delivers Q1 Earnings Beat and Raises 2026 Guidance ↗
Via Chartmill
Topics Earnings
PTC Therapeutics Inc (NASDAQ:PTCT) Stock Slides After Q4 Earnings Miss ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
Via Chartmill
News headline image
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% ↗
This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗
This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology. 
Via The Motley Fool
News headline image
PTC Therapeutics Q1 Earnings Call Highlights ↗
PTC Therapeutics (NASDAQ:PTCT) reported a record first quarter for product revenue and raised its 2026 revenue outlook, citing strong early demand for Sephience, its treatment for phenylketonuria, or... 
Via MarketBeat
Topics Earnings
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines High-Growth Momentum with Bullish Technical Setup ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate ↗
Via Chartmill
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup ↗
Via Chartmill
News headline image
PTCT Q1 2026 Earnings Transcript ↗
PTCT Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
PTC Therapeutics Inc (NASDAQ:PTCT): A Prime Candidate for Affordable Growth Investing ↗
Via Chartmill
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing ↗
PTC Therapeutics develops therapies for rare diseases, with a portfolio spanning commercial products and investigational candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing ↗
This clinical-stage biotech develops antibody therapeutics targeting cancer, with a pipeline focused on oncology and immunotherapy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC THERAPEUTICS INC (NASDAQ:PTCT) Shows High-Growth Momentum and Bullish Technical Setup ↗
PTC Therapeutics stock shows strong earnings momentum and a top-rated technical setup, offering a potential breakout opportunity for growth investors. 
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT) Presents a Compelling Growth and Technical Setup ↗
PTC Therapeutics (PTCT) exemplifies a strong growth stock with a bullish technical setup, combining high sales growth, robust margins, and a potential chart breakout. 
Via Chartmill
News headline image
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Reasonable Valuation ↗
PTC Therapeutics offers high growth at a fair price, with strong earnings and revenue increases, trading below industry valuations. 
Via Chartmill
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
One specialist investor just walked away from STAAR Surgical entirely—right as uncertainty over a delayed Alcon deal looms. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.